Indication
MDS/MPN-unclassifiable
1 clinical trial
5 products
Clinical trial
A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap SyndromesStatus: Recruiting, Estimated PCD: 2025-02-01
Product
VenetoclaxProduct
FludarabineProduct
BusulfanProduct
AzacitidineProduct
Decitabine/cedazuridine